WASHINGTON — The Department of Health and Human Services is gearing up to start releasing details about its new Medicare drug price negotiation process this year, and the public will have more of a chance to weigh in along the way than initially expected, officials said Wednesday.
The Inflation Reduction Act, which established Medicare’s new negotiation powers, didn’t explicitly require the agency to get public input before setting up the program, but HHS outlined several opportunities it will be publicizing anyway. The agency also laid out a detailed timeline of key dates when drugmakers, policy experts, insurers, and patients can expect more details about the Medicare negotiation program.
“We cannot do this important work alone and will engage with the public early and often,” Centers for Medicare and Medicaid Services Administrator Chiquita Brooks-LaSure said in a written statement.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect